Abbott stock price briefly tested $113

Abbott stock price briefly tested $113.20, with momentum backed by favorable FDA approvals for recent product launches. Investors anticipate these approvals could translate into higher quarterly sales volume. With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision. From a fundamental perspective, Abbott Laboratories has a current market capitalization of approximately $230 billion. Over the last twelve months, the company generated $42 billion in revenue. It has demonstrated strong profitability, with $7.1 billion in operating profits and a substantial net income of $14 billion. That said, if you seek upside with lower volatility than individual stocks, the Trefis High Quality portfolio presents an alternative — having outperformed the S&P 500 and generated returns exceeding 91% since its inception. Abbott stock price hovered around $111.75 as investors digested sector research showing stable growth in medical device demand. Analysts suggest the current valuation is justified given strong margins and innovation pipeline.